Articles with public access mandates - Caterina PattiLearn more
Not available anywhere: 1
Response-adapted postinduction strategy in patients with advanced-stage follicular lymphoma: the FOLL12 study
S Luminari, M Manni, S Galimberti, A Versari, A Tucci, C Boccomini, ...
Journal of Clinical Oncology 40 (7), 729-739, 2022
Mandates: Government of Italy
Available somewhere: 18
BRAF Mutations in Hairy-Cell Leukemia
E Tiacci, V Trifonov, G Schiavoni, A Holmes, W Kern, MP Martelli, ...
New England Journal of Medicine 364 (24), 2305-2315, 2011
Mandates: US National Institutes of Health
Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non–germinal center B-cell diffuse large B-cell lymphoma
A Younes, LH Sehn, P Johnson, PL Zinzani, X Hong, J Zhu, C Patti, ...
Journal of Clinical Oncology 37 (15), 1285-1295, 2019
Mandates: US National Institutes of Health
A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma
F Morschhauser, P Feugier, IW Flinn, R Gasiorowski, R Greil, Á Illés, ...
Blood, The Journal of the American Society of Hematology 137 (5), 600-609, 2021
Mandates: US National Institutes of Health
Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma
P Corradini, U Vitolo, A Rambaldi, R Miceli, F Patriarca, A Gallamini, ...
Leukemia 28 (9), 1885-1891, 2014
Mandates: Government of Italy
Randomized trial comparing R-CHOP versus high-dose sequential chemotherapy in high-risk patients with diffuse large B-cell lymphomas
S Cortelazzo, C Tarella, AM Gianni, M Ladetto, AM Barbui, A Rossi, ...
Journal of Clinical Oncology 34 (33), 4015-4022, 2016
Mandates: Government of Italy
MATRix–RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single …
AJM Ferreri, JK Doorduijn, A Re, MG Cabras, J Smith, F Ilariucci, M Luppi, ...
The Lancet Haematology 8 (2), e110-e121, 2021
Mandates: Cancer Research UK, Swiss Cancer Foundation, Swiss Cancer League
The lymphocyte to monocyte ratio improves the IPI‐risk definition of diffuse large B‐cell lymphoma when rituximab is added to chemotherapy
A Rambaldi, C Boschini, G Gritti, F Delaini, E Oldani, A Rossi, AM Barbui, ...
American journal of hematology 88 (12), 1062-1067, 2013
Mandates: Government of Italy
A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma …
M Trnĕný, G Verhoef, MJS Dyer, DB Yehuda, C Patti, M Canales, A Lopez, ...
haematologica 103 (8), 1351, 2018
Mandates: US National Institutes of Health
Consolidation radiotherapy could be safely omitted in advanced Hodgkin lymphoma with large nodal mass in complete metabolic response after ABVD: final analysis of the …
A Gallamini, A Rossi, C Patti, M Picardi, A Romano, M Cantonetti, S Oppi, ...
Journal of Clinical Oncology 38 (33), 3905-3913, 2020
Mandates: AIRC Foundation for Cancer Research in Italy
Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter …
R Bruna, F Benedetti, C Boccomini, C Patti, AM Barbui, A Pulsoni, ...
haematologica 104 (11), 2241, 2019
Mandates: Government of Italy
Phase 2 study evaluating the efficacy and safety of parsaclisib in patients with relapsed or refractory marginal zone lymphoma (CITADEL-204)
TJ Phillips, P Corradini, R Gurion, C Patti, M Tani, A Avigdor, W Jurczak, ...
Blood 136, 27-28, 2020
Mandates: US National Institutes of Health
Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II study
A Chiappella, A Dodero, A Evangelista, A Re, L Orsucci, SV Usai, ...
Leukemia 37 (2), 433-440, 2023
Mandates: AIRC Foundation for Cancer Research in Italy
The neutrophil to lymphocyte ratio (NLR) and the presence of large nodal mass are independent predictors of early response: a subanalysis of the prospective phase II PET‐2 …
A Romano, C Pavoni, F Di Raimondo, C Tarella, S Viviani, A Rossi, ...
Cancer Medicine 9 (23), 8735-8746, 2020
Mandates: AIRC Foundation for Cancer Research in Italy
Real-world outcomes of relapsed/refractory diffuse large B-cell lymphoma treated with polatuzumab vedotin-based therapy
L Argnani, A Broccoli, C Pellegrini, A Fabbri, B Puccini, R Bruna, MC Tisi, ...
Hemasphere 6 (12), e798, 2022
Mandates: Government of Italy
A clinical prognostic model based on machine learning from the Fondazione Italiana Linfomi (FIL) MCL0208 phase III trial
GM Zaccaria, S Ferrero, E Hoster, R Passera, A Evangelista, E Genuardi, ...
Cancers 14 (1), 188, 2021
Mandates: Government of Italy
Anti-PD1 consolidation in patients with Hodgkin lymphoma at high risk of relapse after autologous stem cell transplantation: a multicenter real-life study
R De Filippi, G Marcacci, E Derenzini, M Musso, D Donnarumma, ...
Cancers 14 (23), 5846, 2022
Mandates: Government of Italy
Predictive value on advance hodgkin lymphoma treatment outcome of end‐of treatment FDG PET/CT in the HD0607 clinical trial
A Biggi, S Chauvie, F Fallanca, L Guerra, F Bergesio, M Menga, A Bianchi, ...
Hematological Oncology 41 (3), 415-423, 2023
Mandates: AIRC Foundation for Cancer Research in Italy
Updated 13 Yr Follow-Up of the GITMO-IIL Trial Comparing Upfront R-HDS with Autograft vs. CHOP-R in High-Risk Follicular Lymphoma: Prolonged Survival in Both Arms and a High …
R Bruna, F Benedetti, C Boccomini, C Patti, AM Barbui, A Pulsoni, ...
Mandates: Government of Italy
Publication and funding information is determined automatically by a computer program